ECSP045145A - Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo - Google Patents

Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo

Info

Publication number
ECSP045145A
ECSP045145A EC2004005145A ECSP045145A ECSP045145A EC SP045145 A ECSP045145 A EC SP045145A EC 2004005145 A EC2004005145 A EC 2004005145A EC SP045145 A ECSP045145 A EC SP045145A EC SP045145 A ECSP045145 A EC SP045145A
Authority
EC
Ecuador
Prior art keywords
inhibitors
norepinefrine
recaptation
cognitive failure
failure treatment
Prior art date
Application number
EC2004005145A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Donald Richard Gehlert
David Lee Mckinzie
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP045145A publication Critical patent/ECSP045145A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Inhibidores selectivos de la recaptación de norepinefrina, particularmente atomoxetina, reboxetina y fenoxifenilpropilaminas 2-alquiltiosustituidas, se usan para el tratamiento del fallo cognitivo, incluyendo el fallo cognitivo debido a demencia, delirio y esquizofrenia.
EC2004005145A 2001-12-11 2004-06-09 Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo ECSP045145A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11

Publications (1)

Publication Number Publication Date
ECSP045145A true ECSP045145A (es) 2004-07-23

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005145A ECSP045145A (es) 2001-12-11 2004-06-09 Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo

Country Status (26)

Country Link
US (1) US20050009925A1 (es)
EP (1) EP1458368B1 (es)
JP (1) JP2005517647A (es)
KR (1) KR20040066895A (es)
CN (1) CN1713900A (es)
AU (1) AU2002352625A1 (es)
BR (1) BR0213581A (es)
CA (1) CA2467802A1 (es)
CO (1) CO5590907A2 (es)
CZ (1) CZ2004709A3 (es)
DE (1) DE60223718T2 (es)
EA (1) EA200400793A1 (es)
EC (1) ECSP045145A (es)
ES (1) ES2295435T3 (es)
HR (1) HRPK20040528B3 (es)
HU (1) HUP0402619A3 (es)
IL (1) IL161989A0 (es)
MX (1) MXPA04005716A (es)
MY (1) MY136367A (es)
NO (1) NO20042904L (es)
NZ (1) NZ532065A (es)
PL (1) PL369311A1 (es)
SK (1) SK2442004A3 (es)
TW (1) TW200300672A (es)
WO (1) WO2003049724A1 (es)
ZA (1) ZA200404274B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313411A (pt) * 2002-08-14 2005-06-28 Pharmacia & Upjohn Co Llc Uso de reboxetina para o tratamento de ondas de calor
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
CA2530014A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
US20070015786A1 (en) * 2003-12-12 2007-01-18 Eli Lily And Company Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2005105763A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
EP2764863B1 (en) * 2011-10-03 2020-03-11 National Center for Geriatrics and Gerontology Tau aggregation inhibitor
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2962687B1 (en) 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
PT1196172E (pt) * 1999-07-01 2006-05-31 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para tratar a dor cronica
HUP0203448A3 (en) * 1999-10-13 2005-07-28 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors and pharmaceutical compositions containing them
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory

Also Published As

Publication number Publication date
HRPK20040528B3 (en) 2006-03-31
EP1458368B1 (en) 2007-11-21
HRP20040528A2 (en) 2004-10-31
KR20040066895A (ko) 2004-07-27
EA200400793A1 (ru) 2004-10-28
IL161989A0 (en) 2005-11-20
CZ2004709A3 (cs) 2004-10-13
CO5590907A2 (es) 2005-12-30
JP2005517647A (ja) 2005-06-16
ZA200404274B (en) 2005-09-13
WO2003049724A1 (en) 2003-06-19
MXPA04005716A (es) 2004-12-06
BR0213581A (pt) 2004-08-24
TW200300672A (en) 2003-06-16
ES2295435T3 (es) 2008-04-16
MY136367A (en) 2008-09-30
NZ532065A (en) 2007-03-30
DE60223718T2 (de) 2008-10-30
US20050009925A1 (en) 2005-01-13
CN1713900A (zh) 2005-12-28
NO20042904L (no) 2004-09-07
CA2467802A1 (en) 2003-06-19
AU2002352625A1 (en) 2003-06-23
HUP0402619A2 (hu) 2005-03-29
EP1458368A1 (en) 2004-09-22
HUP0402619A3 (en) 2008-04-28
DE60223718D1 (de) 2008-01-03
PL369311A1 (en) 2005-04-18
SK2442004A3 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
LTC1436271I2 (lt) Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
RS20050392A (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NO20040933L (no) Nye gamma-sekretaseinhibitorer.
ECSP045145A (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo
UY28348A1 (es) Compuestos novedosos
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA200602157A1 (ru) Новые производные тетрагидропиридотиофена
UY28360A1 (es) Nuevos compuestos
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
UY28344A1 (es) Nuevos compuestos
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
MY142214A (en) Prophylactic or therapeutic agent for depression or anxiety disorder
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
EP1841420A4 (en) TREATMENT OF PHARMACORESISTANT PROLIFERATIVE DISEASES
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
CR7368A (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo
AR030750A1 (es) 1-amino-alquilciclohexanos como agentes tripanocidas
ITMI20021328A1 (it) Nuove piperazine 1,4 - disostituite
IL284547A (en) 3 balls with lighting and air conditioning